AUROPHARMA

Ltd's wholly-owned subsidiary Eugia Pharma Specialities received US FDA final approval for Everolimus Tablets, a generic version of Zortress, in strengths of 0.25-1 mg. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zortress Tablets, marketed by Novartis. Eugia has received its 184th ANDA approval with an expected launch in Q1 FY27.